title: Utility of interrupting antiretroviral treatment before HIV drug resistance testing in patients with persistently detectable low-level viremia.
authors.forename: Juan Luis Gûmez
authors.initials: JL
authors.lastname: Sirvent
authors.forename: Marìa Mar Alonso
authors.initials: MM
authors.lastname: Socas
authors.forename: Carlos Hernndez
authors.initials: CH
authors.lastname: Calzadilla
authors.forename: Ana M Lûpez
authors.initials: AM
authors.lastname: Lirola
authors.forename: Marìa Remedios Aleman
authors.initials: MR
authors.lastname: Valls
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D012321:DNA-Directed RNA Polymerases / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D016333:HIV Protease / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D014766:Viremia
chemical_list: D044966:Anti-Retroviral Agents; D012321:DNA-Directed RNA Polymerases; D016333:HIV Protease